Chikusetsusaponin Iva (Calenduloside F)
(Synonyms: 竹节人参皂苷 IVA; Calenduloside F) 目录号 : GC30075An oleanane-type triterpenoid with diverse biological activities
Cas No.:51415-02-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Chikusetsusaponin IVa is an oleanane-type triterpenoid that has been found in P. stipuleanatus and has diverse biological activities.1,2,3 It inhibits the growth of human HL-60 leukemia and HCT116 colon cancer cells (IC50s = 76.23 and 78.11 ?M, respectively).1 Chikusetsusaponin IVa (50-200 ?g/ml) reduces LPS-induced increases in inducible nitric oxide synthase (iNOS), COX-2, IL-1β, IL-6, and TNF-α levels in THP-1 macrophages differentiated with phorbol 12-myristate 13-acetate .2 It decreases plasma glucose, triglyceride, and LDL-cholesterol, and increases HDL-cholesterol, levels in a rat model of type 2 diabetes induced by streptozotocin and a high-fat diet when administered at doses ranging from 45 to 180 mg/kg.3 It also decreases malondialdehyde (MDA), and increases superoxide dismutase (SOD), glutathione (GSH), and glutathione peroxidase 4 (GPX4), levels in the pancreas in the same model.
1.Liang, C., Ding, Y., Nguyen, H.T., et al.Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activitiesBioorg. Med. Chem. Lett.20(23)7110-7115(2010) 2.Wang, H., Qi, J., Li, L., et al.Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cellsInt. J. Immunopathol. Pharmacol.28(3)308-317(2015) 3.Wang, L., Duan, J., Jia, N., et al.IRS-2/Akt/GSK-3β/Nrf2 pathway contributes to the protective effects of Chikusetsu Saponin IVa against lipotoxicityOxid. Med. Cell. Longev.8832318(2021)
Cas No. | 51415-02-2 | SDF | |
别名 | 竹节人参皂苷 IVA; Calenduloside F | ||
Canonical SMILES | O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6C(O)=O)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO | ||
分子式 | C42H66O14 | 分子量 | 794.97 |
溶解度 | DMSO : 100 mg/mL (125.79 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.2579 mL | 6.2895 mL | 12.5791 mL |
5 mM | 0.2516 mL | 1.2579 mL | 2.5158 mL |
10 mM | 0.1258 mL | 0.629 mL | 1.2579 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。